Jaguar health reports approval of all proposals at april 2024 special meeting of stockholders

Company not implementing a reverse split at this time top line results forthcoming for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea san francisco, ca / accesswire / april 9, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced the voting results of the company's special meeting of stockholders held on april 9, 2024 (the "special meeting"). four proposals were submitted to and approved by the stockholders of the company at the special meeting.
JAGX Ratings Summary
JAGX Quant Ranking